13086 Berlin, de
+49 (30) 9240061-0
ProBioGen Announces the Appointment of Dr. Volker Sandig to Chief Scientific Officer
Former CSO Dr. Uwe Marx leaves for academia
Dr. Sandig has established ProBioGen's cell line development program in 2000 and has been responsible for the development of high producer cell lines and the customized design of new cell lines from primary sources. Prior to joining ProBioGen, he held senior management positions at Merck Research Laboratories, USA, focusing on the development of manufacturing systems for gutless adenoviruses. Using his knowledge in viral vectors, he also participated in Merck's vaccine program. Earlier in his career, he designed experimental strategies for adenovirusbased tumor treatment and directed research projects in cell cycle regulation and artificial promoters at Max Planck Society and Hepavec, a Berlinbased biotech company. After finishing medical training, Volker Sandig received his PhD in Molecular Biology from Humboldt University, Berlin.
"We would like to thank Uwe Marx for his important role in the success of ProBioGen. As a founder of the company, he has built a strong team of seasoned scientists over time," commented Hubertus Leonhardt, Chairman of the Board. "We are convinced that Volker Sandig, who has a long track record with ProBioGen, will be an excellent successor to Uwe Marx. Dr. Sandig has not only developed the company's proprietary AGE1 cell lines, he has also been a key scientist in establishing the company's broad technology and product portfolio."
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an email@example.com.